IndieBio

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Avalo is a biotechnology company focused on enhancing crop resilience through innovative gene discovery and control techniques. By employing interpretable machine learning, Avalo accelerates the identification of genes in plants, thereby facilitating the development of improved agricultural crops. The company's artificial intelligence-based platform is designed to uncover the biological origins of traits essential for future agriculture, such as drought tolerance, water-use efficiency, and nutrient density. This advancement in gene discovery not only aids researchers in validating and predicting crop quality but also addresses the challenges posed by a changing climate, contributing to a healthier and more sustainable agricultural landscape.

Avalo is a biotechnology company focused on enhancing crop resilience through innovative gene discovery and control techniques. By employing interpretable machine learning, Avalo accelerates the identification of genes in plants, thereby facilitating the development of improved agricultural crops. The company's artificial intelligence-based platform is designed to uncover the biological origins of traits essential for future agriculture, such as drought tolerance, water-use efficiency, and nutrient density. This advancement in gene discovery not only aids researchers in validating and predicting crop quality but also addresses the challenges posed by a changing climate, contributing to a healthier and more sustainable agricultural landscape.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Ivy Natal is a biotechnology company focused on developing a novel process to create human egg cells from skin samples. By utilizing a skin biopsy technology, the company activates the existing DNA in skin cells to transform them into healthy egg cells. This innovative approach addresses many challenges associated with traditional methods of producing eggs and sperm in vitro, providing a potential solution for various infertility cases. Ivy Natal's technology aims to offer couples, including same-sex couples, the opportunity to have genetically related children.

Ivy Natal is a biotechnology company focused on developing a novel process to create human egg cells from skin samples. By utilizing a skin biopsy technology, the company activates the existing DNA in skin cells to transform them into healthy egg cells. This innovative approach addresses many challenges associated with traditional methods of producing eggs and sperm in vitro, providing a potential solution for various infertility cases. Ivy Natal's technology aims to offer couples, including same-sex couples, the opportunity to have genetically related children.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.

Osiris Bio

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.

Onconetics Pharmaceuticals, Inc. is a biotech company focused on developing innovative gene therapies aimed at targeting tumor cells based on specific gene expression profiles. By utilizing a genetic switch to activate an apoptotic inducer, the therapies aim to eliminate cancer cells while preserving healthy tissue. Founded in 2016 and located in Mill Valley, California, the company is dedicated to advancing personalized medicine, particularly in the treatment of cancer and genetic disorders. Onconetics combines established gene therapy techniques with cutting-edge research to create novel treatments that seek to minimize the invasiveness, cost, and uncertainty associated with traditional cancer therapies. The goal is to develop simpler and more versatile personalized therapies that maintain patient quality of life and enhance understanding of genetic conditions.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

DNA sequencing is driving the new genomic revolution but it’s currently bottlenecked with high compute costs and inaccuracies. Genome Surveillance is revolutionizing DNA sequencing to make it ten times faster and more accurate through reducing the heavy computational load and dropping it to a fraction of the cost of current technologies.

Amaryllis Nucleics, Inc. is a biotechnology company based in Berkeley, California, specializing in the manufacture of RNA sequencing library synthesis kits. Founded in 2016, the company provides a range of RNA sequencing solutions, including kits for detecting differential gene expression, splice variants, exonic polymorphisms, and gene fusions, as well as 3'-digital gene expression kits for comprehensive gene expression studies. Amaryllis Nucleics also offers RNA sequencing services, catering to applications in cancer diagnostics, pharmaceutical development, and food security. By focusing on reducing the time and cost associated with RNA sequencing, the company aims to empower researchers and facilitate significant advancements in genomics. Its products are available for purchase online.

Amino Labs Inc. is a biotechnology company founded in 2015 and based in Canada that focuses on making genetic engineering accessible to a wider audience. The company has developed an intuitive bioengineering mini-lab, a compact continuous bioreactor designed to facilitate bacterial transformations and the continuous growth of various cultures. This user-friendly equipment allows individuals, including those as young as eight, to experiment with genetic engineering, fostering a new generation of bioengineers. The bioreactor serves as a countertop-sized laboratory, providing educational opportunities to learn about DNA, genes, and cell theory, while enabling users to create a diverse range of products, including fragrances, flavors, materials, and medicines. By democratizing access to biotechnology, Amino Labs aims to contribute to personalized manufacturing and address significant global challenges related to food, fuel, and medicine.

Genesis DNA is taking a fundamentally new approach to gene synthesis, the process of turning digital text like ACTG into physical DNA. Their proprietary method circumvents the cost, turnaround time, and sequence limiting factors of existing synthesis methods. Genesis was founded by a team of students at Stanford and MIT that have experienced the pain of current DNA construction methods first hand. They started Genesis DNA with the vision that every researcher should have fast, affordable, and secure access to any DNA sequence they need. They believe the next technology revolution will be a biological one.

At DtoR they have developed the PCR of gene expression—a disruptive technology that will revolutionize the tools used to “tune” protein production in any organism. In one step, and for any cell type, they can identify all of the switches regulating expression of the genome, as well as how active they are. They can also rapidly evolve or synthesize new switches to adapt to any application. Applications developed using their platform will lead to improved product yields in bioreactors, engineered specialty crops, optimized cancer therapeutics, and much more. The possibilities are limited only by their partners' imaginations.

Girihlet Inc. is a genetic-sequencing company based in Oakland, California, established in 2012. It specializes in providing rapid and accurate deep sequencing services, focusing on non-canonical genomics solutions. The company employs novel, bias-free methods to inexpensively sequence and analyze mitochondrial DNA and T cell receptors. By profiling the T cell receptor repertoire, Girihlet aims to improve understanding of the immune system, particularly in relation to T-cell-driven autoimmune conditions. The company leverages deep sequencing and machine learning to decode individual immune responses, thereby guiding therapeutic strategies and enhancing diagnostic capabilities for various disorders. Through its patented technologies, Girihlet seeks to make a significant impact in clinical settings and advance basic research in immunology.

Ranomics, Inc. is a biotechnology company established in 2015, with headquarters in San Francisco, California, and an additional location in Toronto, Canada. The company specializes in providing a comprehensive database of rare genetic variations and associated disease risks, aimed at enhancing the understanding of how genetic makeup influences health. Ranomics offers tools such as RanomicsDB, a query interface that supports variant call format (VCF) data, and the Ranomics API, which allows developers to integrate genetic data into their existing software for variant interpretation. By delivering insights into genetic variations and health predictions, Ranomics enables healthcare professionals to assess genetic changes efficiently and cost-effectively, thereby contributing to advancements in personalized medicine and drug discovery.